Literature DB >> 25601945

Anxiety and depression among amyloid light-chain cardiac amyloidosis patients: The role of life satisfaction.

Martina Smorti1, Silvia Guarnieri2, Franco Bergesio3, Federico Perfetto3, Francesco Cappelli4.   

Abstract

BACKGROUND: The present study aimed to provide a contribution to the study of a rare disease, amyloid light-chain (AL) cardiac amyloidosis, which is the most common type of systemic amyloidosis. In AL amyloidosis prognosis is determined by cardiac involvement. Although the association between psychological distress (e.g. anxiety and depression) and AL cardiac amyloidosis is documented, very little is known about the psychosocial variables that may mediate the association. AIMS: The aim of the study is therefore to examine the potential mediating role of life satisfaction in the relationship between cardiac symptom severity (independent variable) and anxious and depressive symptoms (dependent variables) in AL patients.
METHOD: Forty-three AL amyloidosis patients (57.1% males) with cardiac amyloidosis were administered the Satisfaction with Life Scale, the State-Trait Anxiety Inventory and the Centre for Epidemiological Study-Depression Scale. Clinical variables such as months since cardiac symptom onset and cardiac symptom severity were collected.
RESULTS: Findings showed significant relationships between symptom severity and psychological disorders (e.g. anxiety and depression) and these were mediated by life satisfaction.
CONCLUSION: Overall, findings highlight the importance of subjective well-being (e.g. life satisfaction) to reduce anxious and depressive symptoms and to improve general health in AL patients. © The European Society of Cardiology 2015.

Entities:  

Keywords:  AL amyloidosis; anxiety; depression; life satisfaction

Mesh:

Year:  2015        PMID: 25601945     DOI: 10.1177/1474515114566737

Source DB:  PubMed          Journal:  Eur J Cardiovasc Nurs        ISSN: 1474-5151            Impact factor:   3.908


  3 in total

1.  The burden of amyloid light chain amyloidosis on health-related quality of life.

Authors:  Martha Bayliss; Kristen L McCausland; Spencer D Guthrie; Michelle K White
Journal:  Orphanet J Rare Dis       Date:  2017-01-19       Impact factor: 4.123

2.  Treatment Tolerability in Patients with Immunoglobulin Light-Chain Amyloidosis.

Authors:  Avery A Rizio; Michelle K White; Kristen L McCausland; Tiffany P Quock; Spencer D Guthrie; Miyo Yokota; Martha S Bayliss
Journal:  Am Health Drug Benefits       Date:  2018-11

3.  Content validation of the SF-36v2® health survey with AL amyloidosis patients.

Authors:  Michelle K White; Martha S Bayliss; Spencer D Guthrie; Kimberly P Raymond; Avery A Rizio; Kristen L McCausland
Journal:  J Patient Rep Outcomes       Date:  2017-12-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.